BRIEF published on 12/20/2024 at 07:05, 1 year 10 months ago Innate Pharma at the 43rd JP Morgan Healthcare Conference Investors Immunotherapy Innate Pharma JP Morgan Conference Live Presentation
PRESS RELEASE published on 12/20/2024 at 07:00, 1 year 10 months ago Inside Information / Other news releases Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference with CEO Jonathan Dickinson and other executives presenting. Company focuses on developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients J.P. Morgan Healthcare Conference
BRIEF published on 12/06/2024 at 07:05, 1 year 10 months ago Innate Pharma: Investment of 7.9 million dollars for IPH6501 Investment Clinical Trial Innate Pharma IPH6501 Follicular Lymphoma
BRIEF published on 11/20/2024 at 07:05, 1 year 11 months ago Innate Pharma unveils its financial calendar for 2025 Annual Results Innate Pharma Financial Calendar 2025 Assemblies And Publications Euronext And Nasdaq Contribution
PRESS RELEASE published on 11/20/2024 at 07:00, 1 year 11 months ago Inside Information / Other news releases Innate Pharma releases its 2025 financial calendar including key publication dates for financial statements and shareholder meetings Financial Statements Investors Financial Calendar 2025 Innate Pharma
BRIEF published on 11/08/2024 at 07:05, 1 year 11 months ago Innate Pharma presents its innovations in oncology at SITC 2024 Immunotherapy Innate Pharma SITC 2024 NK Cell Engage Antibody-drug Conjugate
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year 11 months ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
BRIEF published on 06/17/2024 at 07:05, 2 years 4 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 2 years 4 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 2 years 5 months ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
Published on 11/05/2026 at 11:00, 1 hour 42 minutes ago Strategic Metals Ltd. Announces Acquisition of Control and Direction of Additional Securities of GGL Resources Corp.
Published on 11/05/2026 at 08:00, 4 hours 42 minutes ago Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
Published on 11/04/2026 at 23:10, 13 hours 32 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 13 hours 42 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/05/2026 at 12:00, 42 minutes ago Original-Research: SMARTBROKER HOLDING AG (von GBC AG): BUY
Published on 11/05/2026 at 11:57, 45 minutes ago Enapter AG: Capital increase with subscription rights launched
Published on 11/05/2026 at 11:32, 1 hour 10 minutes ago thyssenkrupp nucera Commissions Major Chlor-Alkali Plant for Kutch Chemical in India
Published on 11/05/2026 at 11:15, 1 hour 27 minutes ago Original-Research: Wacker Chemie (von Parmantier & Cie. GmbH): BUY
Published on 11/05/2026 at 10:16, 2 hours 26 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
Published on 11/05/2026 at 07:00, 5 hours 42 minutes ago Eurazeo’s European asset management platform continues to gain momentum, driven by sustained international fundraising
Published on 11/05/2026 at 07:00, 5 hours 42 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
Published on 11/04/2026 at 18:00, 18 hours 42 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
